Trial Profile
An Open, Randomized, Rehabilitation-controlled Study to Assess Safety, Tolerability, and Efficacy of Heparin Activated Recombinant Human Fibroblast Growth Factor 1 on a Biodegradable Device in Subjects with Traumatic Spinal Cord Injury
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 31 Mar 2022
Price :
$35
*
At a glance
- Drugs SC 0806 (Primary)
- Indications Spinal cord injuries
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors BioArctic
- 31 Mar 2022 This trial has been completed in Finland (Date of the global end of the trial : 25-Sep-2020), according to European Clinical Trials Database record.
- 14 Jan 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 14 Jan 2020 Planned primary completion date changed from 1 Oct 2019 to 1 Oct 2020.